Sera Prognostics, Inc. (NASDAQ:SERA) Insider Robert Gardner Harrison Sells 2,264 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) insider Robert Gardner Harrison sold 2,264 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $6.47, for a total value of $14,648.08. Following the completion of the sale, the insider now directly owns 114,573 shares in the company, valued at $741,287.31. This represents a 1.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Robert Gardner Harrison also recently made the following trade(s):

• On Friday, January 10th, Robert Gardner Harrison sold 14,209 shares of Sera Prognostics stock. The stock was sold at an average price of $7.39, for a total value of $105,004.51.

Sera Prognostics Trading Up 3.8 %

Shares of NASDAQ SERA opened at $6.61 on Thursday. The firm has a 50-day moving average of $7.44 and a two-hundred day moving average of $7.31. The company has a market capitalization of $223.23 million, a price-to-earnings ratio of -6.68 and a beta of 0.86. Sera Prognostics, Inc. has a twelve month low of $4.98 and a twelve month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same period last year, the firm earned ($0.23) EPS. As a group, research analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors and hedge funds have recently modified their holdings of SERA. Quest Partners LLC boosted its position in shares of Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Sera Prognostics during the second quarter valued at about $68,000. SG Americas Securities LLC acquired a new position in shares of Sera Prognostics in the third quarter worth about $78,000. Prime Capital Investment Advisors LLC acquired a new stake in shares of Sera Prognostics during the third quarter valued at approximately $104,000. Finally, Jane Street Group LLC lifted its position in shares of Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after acquiring an additional 2,826 shares in the last quarter. 54.64% of the stock is owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.